Status:
TERMINATED
Prevention of Asthma With Levocetirizine (36 Month Treatment) in Young Children Suffering From Eczema (Atopic Dermatitis) and Sensitized to Grass Pollen and House Dust Mite and Having Completed the Previous EPAAC Trial (NCT00152464)
Lead Sponsor:
UCB Pharma
Conditions:
Asthma
Eligibility:
All Genders
30-42 years
Phase:
PHASE3
Brief Summary
Prolongation of the EPAAC™ trial - NCT00152464 (The Early Prevention of Asthma in Atopic Children). 36 months study to evaluate the efficacy and safety of levocetirizine (LCTZ) in preventing the onse...
Eligibility Criteria
Inclusion
- Inclusion criteria which must be verified at the end of first 18-months treatment (Visit 9)
- Having completed the previous 18-month treatment period of the EPAAC trial - NCT00152464
Exclusion
- None
Key Trial Info
Start Date :
June 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2006
Estimated Enrollment :
207 Patients enrolled
Trial Details
Trial ID
NCT00160563
Start Date
June 1 2004
End Date
March 1 2006
Last Update
March 3 2015
Active Locations (51)
Enter a location and click search to find clinical trials sorted by distance.
1
North Adelaide, Australia
2
Parkville (North Melbourne), Australia
3
Brussels, Belgium
4
Brno, Czechia